Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard?
- PMID: 29672417
- PMCID: PMC6037551
- DOI: 10.1097/SLA.0000000000002783
Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard?
Comment on
- 
  
  Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.Ann Surg. 2018 Aug;268(2):215-222. doi: 10.1097/SLA.0000000000002705. Ann Surg. 2018. PMID: 29462005 Clinical Trial.
References
- 
    - Cloyd JM, et al. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017;21(1):164–174. - PubMed
 
- 
    - Tempero MA, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(8):1028–1061. - PubMed
 
- 
    - Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(21):2541–56. - PubMed
 
- 
    - Casadei R, et al. Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets. J Gastrointest Surg. 2015;19(10):1802–12. - PubMed
 
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Medical
 
        